NZ759295A - 5-5 fused rings as c5a inhibitors - Google Patents
5-5 fused rings as c5a inhibitorsInfo
- Publication number
- NZ759295A NZ759295A NZ759295A NZ75929518A NZ759295A NZ 759295 A NZ759295 A NZ 759295A NZ 759295 A NZ759295 A NZ 759295A NZ 75929518 A NZ75929518 A NZ 75929518A NZ 759295 A NZ759295 A NZ 759295A
- Authority
- NZ
- New Zealand
- Prior art keywords
- inhibitors
- fused rings
- modulators
- receptor
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Crystal Substances (AREA)
- Glass Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Insulating Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513025P | 2017-05-31 | 2017-05-31 | |
| PCT/US2018/034908 WO2018222601A1 (en) | 2017-05-31 | 2018-05-29 | 5-5 FUSED RINGS AS C5a INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ759295A true NZ759295A (en) | 2026-03-27 |
Family
ID=64455572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ759295A NZ759295A (en) | 2017-05-31 | 2018-05-29 | 5-5 fused rings as c5a inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10683294B2 (enExample) |
| EP (1) | EP3630774B1 (enExample) |
| JP (1) | JP7141129B2 (enExample) |
| KR (1) | KR102586710B1 (enExample) |
| CN (1) | CN111032658B (enExample) |
| AR (1) | AR111841A1 (enExample) |
| AU (1) | AU2018277523B2 (enExample) |
| CA (1) | CA3064025A1 (enExample) |
| ES (1) | ES2934507T3 (enExample) |
| IL (1) | IL270842B2 (enExample) |
| MA (1) | MA48800A (enExample) |
| MX (1) | MX391392B (enExample) |
| NZ (1) | NZ759295A (enExample) |
| TW (1) | TWI813570B (enExample) |
| WO (1) | WO2018222601A1 (enExample) |
| ZA (1) | ZA201907755B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ759297A (en) | 2017-05-31 | 2026-03-27 | Chemocentryx Inc | 6-5 fused rings as c5a inhibitors |
| KR102586710B1 (ko) | 2017-05-31 | 2023-10-10 | 케모센트릭스, 인크. | C5a 억제제로서의 5-5 융합 고리 |
| WO2019126424A1 (en) | 2017-12-22 | 2019-06-27 | Chemocentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| CN111788184B (zh) * | 2017-12-22 | 2023-12-22 | 凯莫森特里克斯股份有限公司 | 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物 |
| ES2993034T3 (en) * | 2018-04-02 | 2024-12-20 | Chemocentryx Inc | Prodrugs of fused-bicyclic c5ar antagonists |
| US11872217B2 (en) | 2019-07-10 | 2024-01-16 | Chemocentryx, Inc. | Indanes as PD-L1 inhibitors |
| CN112300169B (zh) * | 2019-07-26 | 2022-03-04 | 上海美迪西生物医药股份有限公司 | 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| CN116249692B (zh) * | 2020-09-28 | 2024-08-23 | 四川科伦博泰生物医药股份有限公司 | 吡唑类化合物及其制备方法和用途 |
| MX2023004801A (es) | 2020-10-28 | 2023-05-10 | Chemocentryx Inc | Metodos de tratamiento de hidradenitis supurativa. |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4555547B2 (ja) | 2000-08-10 | 2010-10-06 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物 |
| DE60039921D1 (de) | 2000-09-29 | 2008-09-25 | Neurogen Corp | Hochaffine kleinmolekülige c5a-rezeptor-modulatoren |
| SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
| JP4196678B2 (ja) | 2001-04-26 | 2008-12-17 | 味の素株式会社 | 複素環化合物 |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| AU2003225971A1 (en) | 2002-03-28 | 2003-10-13 | Yang Gao | Substituted biaryl amides as c5a receptor modulators |
| WO2003082828A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| JP2005530719A (ja) | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | 病原性炎症要素を有する状態の治療のための組み合わせ療法 |
| AU2003265395A1 (en) | 2002-08-14 | 2004-03-03 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US20070112015A1 (en) * | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| US20100035875A1 (en) | 2008-06-20 | 2010-02-11 | Bing-Yan Zhu | Triazolopyridine jak inhibitor compounds and methods |
| SMT202200074T1 (it) | 2008-12-22 | 2022-03-21 | Chemocentryx Inc | Antagonisti di c5ar |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| JP6250674B2 (ja) * | 2012-08-16 | 2017-12-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎ型カルシウムチャネル遮断剤としてのピロロピラゾール |
| CN103421006B (zh) | 2013-08-18 | 2016-06-22 | 上海师范大学 | 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用 |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2017176620A2 (en) | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | SOLUBLE C5aR ANTAGONISTS |
| NZ759297A (en) | 2017-05-31 | 2026-03-27 | Chemocentryx Inc | 6-5 fused rings as c5a inhibitors |
| KR102586710B1 (ko) | 2017-05-31 | 2023-10-10 | 케모센트릭스, 인크. | C5a 억제제로서의 5-5 융합 고리 |
| CN111788184B (zh) | 2017-12-22 | 2023-12-22 | 凯莫森特里克斯股份有限公司 | 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物 |
| WO2019126424A1 (en) | 2017-12-22 | 2019-06-27 | Chemocentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| ES2993034T3 (en) | 2018-04-02 | 2024-12-20 | Chemocentryx Inc | Prodrugs of fused-bicyclic c5ar antagonists |
-
2018
- 2018-05-29 KR KR1020197038670A patent/KR102586710B1/ko active Active
- 2018-05-29 MA MA048800A patent/MA48800A/fr unknown
- 2018-05-29 ES ES18809125T patent/ES2934507T3/es active Active
- 2018-05-29 US US15/991,747 patent/US10683294B2/en active Active
- 2018-05-29 MX MX2019014292A patent/MX391392B/es unknown
- 2018-05-29 AU AU2018277523A patent/AU2018277523B2/en active Active
- 2018-05-29 NZ NZ759295A patent/NZ759295A/en unknown
- 2018-05-29 EP EP18809125.0A patent/EP3630774B1/en active Active
- 2018-05-29 CN CN201880036650.8A patent/CN111032658B/zh active Active
- 2018-05-29 CA CA3064025A patent/CA3064025A1/en active Pending
- 2018-05-29 WO PCT/US2018/034908 patent/WO2018222601A1/en not_active Ceased
- 2018-05-29 JP JP2019565826A patent/JP7141129B2/ja active Active
- 2018-05-31 AR ARP180101445A patent/AR111841A1/es unknown
- 2018-05-31 TW TW107118603A patent/TWI813570B/zh active
-
2019
- 2019-11-21 IL IL270842A patent/IL270842B2/en unknown
- 2019-11-22 ZA ZA2019/07755A patent/ZA201907755B/en unknown
-
2020
- 2020-05-04 US US16/865,648 patent/US11479553B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3630774B1 (en) | 2022-11-23 |
| JP7141129B2 (ja) | 2022-09-22 |
| IL270842A (en) | 2020-01-30 |
| RU2019142985A (ru) | 2021-06-30 |
| MX391392B (es) | 2025-03-21 |
| TWI813570B (zh) | 2023-09-01 |
| EP3630774A4 (en) | 2020-10-07 |
| WO2018222601A1 (en) | 2018-12-06 |
| AR111841A1 (es) | 2019-08-21 |
| TW201902897A (zh) | 2019-01-16 |
| KR20200013720A (ko) | 2020-02-07 |
| US10683294B2 (en) | 2020-06-16 |
| CN111032658A (zh) | 2020-04-17 |
| RU2019142985A3 (enExample) | 2021-09-03 |
| AU2018277523A1 (en) | 2019-12-05 |
| KR102586710B1 (ko) | 2023-10-10 |
| AU2018277523B2 (en) | 2022-06-23 |
| MA48800A (fr) | 2020-04-08 |
| EP3630774A1 (en) | 2020-04-08 |
| ES2934507T3 (es) | 2023-02-22 |
| BR112019025230A2 (pt) | 2020-06-16 |
| JP2020522483A (ja) | 2020-07-30 |
| US20210009594A1 (en) | 2021-01-14 |
| CN111032658B (zh) | 2022-12-20 |
| ZA201907755B (en) | 2023-05-31 |
| US11479553B2 (en) | 2022-10-25 |
| IL270842B1 (en) | 2023-01-01 |
| US20180346471A1 (en) | 2018-12-06 |
| CA3064025A1 (en) | 2018-12-06 |
| MX2019014292A (es) | 2022-04-07 |
| IL270842B2 (en) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907746B (en) | 6-5 fused rings as c5a inhibitors | |
| MX2019014292A (es) | Anillos 5-5 fusionados como inhibidores c5a. | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| ZA202006154B (en) | Prodrugs of fused-bicyclic c5ar antagonists | |
| MX2020006460A (es) | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| NZ737399A (en) | Ccr2 modulators | |
| EP4356969A3 (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| TW201613864A (en) | Novel compounds | |
| MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
| PH12018500432A1 (en) | Heteroaryl compounds and their use as therapeutic drugs | |
| PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| PH12018501563A1 (en) | Indane derivatives as mglur7 modulators | |
| JOP20200104A1 (ar) | مركبات مثبطة لـ btk | |
| MX375329B (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| MX2014013240A (es) | Composicion farmaceutica para el tratamiento de la disfuncion erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en tabletas. |